

# Edward J Tanner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7577905/publications.pdf>

Version: 2024-02-01

79  
papers

3,018  
citations

159358

30  
h-index

168136

53  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3636  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. <i>Gynecologic Oncology</i> , 2017, 146, 405-415.	0.6	298
2	Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 459-476.e10.	0.7	241
3	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
4	A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 281-286.	0.6	134
5	FTO-Dependent <i>N<sup>6</sup></i> -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. <i>Cancer Research</i> , 2020, 80, 3200-3214.	0.4	128
6	Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. <i>Cancer Research</i> , 2021, 81, 384-399.	0.4	113
7	Lymphopenia and its association with survival in patients with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2016, 140, 76-82.	0.6	110
8	Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 542-547.	0.6	101
9	High grade undifferentiated uterine sarcoma: Surgery, treatment, and survival outcomes. <i>Gynecologic Oncology</i> , 2012, 127, 27-31.	0.6	89
10	Management of uterine adenosarcomas with and without sarcomatous overgrowth. <i>Gynecologic Oncology</i> , 2013, 129, 140-144.	0.6	83
11	Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 497.e1-497.e10.	0.7	75
12	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017, 147, 85-91.	0.6	74
13	The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2011, 123, 548-552.	0.6	70
14	Laparoscopy in the Morbidly Obese: Physiologic Considerations and Surgical Techniques to Optimize Success. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 182-195.	0.3	70
15	A microRNA survival signature (MiSS) for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 444-450.	0.6	69
16	Utilization of Minimally Invasive Surgery in Endometrial Cancer Care. <i>Obstetrics and Gynecology</i> , 2016, 127, 91-100.	1.2	69
17	Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?. <i>Gynecologic Oncology</i> , 2010, 117, 336-340.	0.6	67
18	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. <i>Gynecologic Oncology</i> , 2018, 148, 480-484.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 302-306.	0.6	54
20	Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?. <i>Gynecologic Oncology</i> , 2013, 131, 629-633.	0.6	51
21	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 132, 560-565.	0.6	50
22	Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 143, 281-286.	0.6	38
23	Disparities in Surgical Care Among Women With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 526-534.	1.2	38
24	Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation. <i>Gynecologic Oncology</i> , 2018, 149, 554-559.	0.6	38
25	Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 756-764.	1.2	36
26	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. <i>Gynecologic Oncology</i> , 2018, 150, 426-431.	0.6	36
27	Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: Risk factors and associations with postoperative morbidity. <i>Gynecologic Oncology</i> , 2013, 131, 525-530.	0.6	35
28	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	0.6	35
29	The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. <i>Gynecologic Oncology</i> , 2020, 157, 348-356.	0.6	35
30	Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 124, 59-62.	0.6	32
31	Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology. <i>Gynecologic Oncology</i> , 2016, 143, 604-610.	0.6	31
32	Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 234-238.	0.6	30
33	Risk of empty lymph node packets in sentinel lymph node mapping for endometrial cancer using indocyanine green. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 513-517.	1.2	30
34	Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2012, 126, 224-228.	0.6	29
35	Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 535-540.	0.6	29
36	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	28

#	ARTICLE	IF	CITATIONS
37	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Carcinoma: Analysis of 30-Day Morbidity and Mortality. <i>Annals of Surgical Oncology</i> , 2015, 22, 655-661.	0.7	22
38	Feasibility of Robotic-Assisted Laparoendoscopic Single-Site Surgery in the Gynecologic Oncology Setting. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 258-263.	0.3	22
39	Single site robotic sentinel lymph node biopsy and hysterectomy in endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 137, 190.	0.6	19
40	Comparing Single-Site and Multiport Robotic Hysterectomy with Sentinel Lymph Node Mapping for Endometrial Cancer: Surgical Outcomes and Cost Analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 977-983.	0.3	19
41	ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5516-5516.	0.8	19
42	Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 58-63.	0.6	17
43	The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1416-1421.	1.2	16
44	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	0.6	16
45	Prognostic Significance of the Number of Postoperative Intraperitoneal Chemotherapy Cycles for Patients With Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 599-606.	1.2	13
46	HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 708-715.	2.1	13
47	FOXP2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
48	Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. <i>Gynecologic Oncology</i> , 2021, 160, 625-632.	0.6	12
49	Prophylactic salpingectomy in premenopausal women at low risk for ovarian cancer: risk-reducing or risky?. <i>Fertility and Sterility</i> , 2013, 100, 1530-1531.	0.5	11
50	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2013, 128, 28-33.	0.6	11
51	A Comparison of Thermal Plasma Energy Versus Argon Beam Coagulator-Induced Intestinal Injury After Vaporization in a Porcine Model. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 177-182.	1.2	11
52	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	0.6	10
53	Controversies in Sentinel Lymph Node Biopsy for Gynecologic Malignancies. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 409-417.	0.3	10
54	Robotic laparoendoscopic single site radical hysterectomy with sentinel lymph node mapping and pelvic lymphadenectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 387.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Radical Surgery With Individualized Postoperative Radiation for Stage IB Cervical Cancer: Oncologic Outcomes and Severe Complications. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 553-558.	1.2	8
56	The Use of "Optimal Cytoreduction" Nomenclature in Ovarian Cancer Literature: Can We Move Toward a More Optimal Classification System?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1421-1427.	1.2	8
57	Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6025-6025.	0.8	8
58	Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 118.	1.3	7
59	Surgical care of young women diagnosed with ovarian cancer: A population-based perspective. <i>Gynecologic Oncology</i> , 2008, 111, 221-225.	0.6	6
60	Where Are We Going with Sentinel Lymph Node Mapping in Gynecologic Cancers?. <i>Current Oncology Reports</i> , 2018, 20, 96.	1.8	5
61	Feasibility and Prediction of Adverse Events in a Postoperative Monitoring Program of Patient-Reported Outcomes and a Wearable Device Among Gynecologic Oncology Patients. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100167.	1.0	4
62	Evaluation of Liquid From the Papanicolaou Test and Other Liquid Biopsies for the Detection of Endometrial and Ovarian Cancers. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 463-464.	0.2	3
63	Minimally Invasive Surgery Rate as a Quality Metric for Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1389-1394.	0.3	3
64	Laparoscopic surgical access in morbidly obese women undergoing endometrial cancer surgery: Repurposing the left upper quadrant approach. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 244, 56-59.	0.5	3
65	Discrepancies between author- and industry-reported disclosures of financial relationships at an annual gynecologic oncology research meeting. <i>Gynecologic Oncology</i> , 2021, 160, 260-264.	0.6	3
66	Management and Recommendations for Future Pregnancy in Patients with Early-Stage Endometrial Cancer: A Survey of Gynecologic Oncologists and Reproductive Endocrinology and Infertility Specialists. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, , .	0.7	3
67	Treatment of vulvar and vaginal dysplasia: plasma energy ablation versus carbon dioxide laser ablation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1410-1415.	1.2	3
68	Gynecologic Care in Women With Down Syndrome. <i>Obstetrics and Gynecology</i> , 2020, 136, 518-523.	1.2	2
69	Association between surgical approach and survival following resection of abdominopelvic malignancies. <i>Journal of Surgical Oncology</i> , 2020, 121, 620-629.	0.8	2
70	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
71	Surgical Training in Gynecologic Oncology:A Sea Change. <i>Journal of Gynecologic Surgery</i> , 0, , .	0.0	1
72	A Comparison of Primary Intraperitoneal Chemotherapy to Consolidation Intraperitoneal Chemotherapy in Optimally Resected Advanced Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2014, 69, 741-742.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Sentinel Lymph Node Mapping in Gynecologic Cancers. Current Obstetrics and Gynecology Reports, 2015, 4, 159-165.	0.3	0
74	Updates in Sentinel Lymph Node Mapping in Gynecologic Cancer. Current Obstetrics and Gynecology Reports, 2018, 7, 28-38.	0.3	0
75	Indications and Contraindications to Robotic-Assisted Hysterectomy. , 2018, , 763-769.		0
76	Instrumentation, Platforms, and Basic Principles of Robotics. , 2014, , 185-195.		0
77	Effect of lymphopenia on survival in women with cervical cancer treated with primary chemoradiation.. Journal of Clinical Oncology, 2014, 32, e16507-e16507.	0.8	0
78	Abstract 3672: Role and presence of cancer associated fibroblasts and M2 macrophages in high grade cervical intraepithelial neoplasia and invasive cervical carcinomas. , 2014, , .		0
79	Planning treatment for women with recurrent epithelial ovarian cancer. Oncology, 2013, 27, 304, 306.	0.4	0